On The Fly
|
Want to get stock-moving… ShowHide Related Items >><< - 02/28/23
- Universal Health falls -10.5%
- $151.32 /
+29.13 (+23.84%) - 02/17/23
- Sarepta announces first patient dosed in SRP-9003-102 study
- 02/13/23
- Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4
- 01/05/23
- Catalent, Sarepta expand commercial collaboration with deal for DMD candidate
- 11/28/22
- Sarepta announces FDA grants priority review for SRP-9001 BLA
- 03/01/23
- Spirit AeroSystems enters MRO agreement with Joramco
- 11/07/22
- Spirit AeroSystems rises 13.1%
- 10/19/22
- Spirit AeroSystems enters MOU with Joramco for MRO services cooperation
- 09/21/22
- Spirit AeroSystems enters MOU with MAB to develop MRO services for 737 aircraft
- 01/31/23
- Spotify rises 9.8%
- 01/31/23
- Spotify reports Q4 MAUs up 20% y/y to 489M
- 01/26/23
- Spotify tweets 'everything's looking much better now'
- 01/26/23
- Spotify says 'something's not quite right,' company investigating
- 02/28/23
- Rivian Automotive down 6% following quarterly report
- 02/28/23
- Rivian Automotive sees 50,000 vehicles produced in 2023
- 02/14/23
- Greenlight buys Tenet, exits Intel in Q4
- 01/29/23
- Philip Morris announces agreement to extend, deepen collaboration with KT&G
- 01/26/23
- FDA authorizes three new Marlboro heated tobacco products
- 01/22/23
- Fly Intel: Top five weekend stock stories
- 01/08/23
- Fly Intel: Top five weekend stock stories
- 02/14/23
- Palantir rises 12.7%
- 02/14/23
- Palantir rises 10.8%
- 02/14/23
- Palantir rises 9.6%
- 02/13/23
- Palantir jumps 18% to $8.99 after reporting profitable quarter
- 02/14/23
- Nelson Peltz's Trian buys Disney, cuts Sysco in Q4
- 01/19/23
- Procter & Gamble says 'on track' to deliver FY23 guidance
- 01/19/23
- Procter & Gamble says Q2 growth broad based across business units
- 01/19/23
- Procter & Gamble reports Q2 gross margin down 160 bps vs. a year ago
- 02/23/23
- Marqeta appoints Crystal Sumner as Chief Legal Officer
- 01/30/23
- Marqeta acquires Power Finance for $223M cash plus $52M milestone
- 01/26/23
- Marqeta names Simon Khalaf as CEO
- 12/07/22
- Marqeta integrates with Mastercard Track Instant Pay virtual card solution
- 02/27/23
- MKS Instruments sees ransomware incident having material impact on Q1 results
- 02/13/23
- MKS Instruments reschedules Q4, 2022 earnings call due to ransomware event
- 12/14/22
- MKS Instruments presents long-term strategy, financial outlook at Analyst Day
- 11/01/22
- MKS Instruments appoints Chang as Senior Vice President, General Manager, Asia
- 03/01/23
- Cidara Therapeutics announces interim Phase 2a data of CD388
- 02/23/23
- Zhongchao renews partnership with Johnson & Johnson China
- 02/14/23
- Johnson & Johnson appoints Dr. John Reed as EVP of Pharmaceuticals, R&D
- 02/09/23
- Roche expands collaboration with Janssen to create companion diagnostics
- 12/14/22
- Cerence enters partnerships with iHeartMedia, Radioline
- 11/28/22
- California AG announces settlements against Google, iHeartMedia over radio ads
- 11/28/22
- FTC, state AGs announce settlement with Google and iHeartMedia over Pixel 4 ads
- 09/23/22
- iHeartMedia, Neustar announce new marketing partnership
- 11/09/22
- Uber, Grocery Outlet expand partnership
- 11/08/22
- Grocery Outlet announces CEO transition plan, Sheedy to become CEO
- 12/19/22
- ANI Pharmaceuticals announces FDA approval of ANDA for Levocarnitine Tablets
- 11/28/22
- ANI Pharmaceuticals receives FDA approval for ANDA for Fluoxetine Oral Solution
- 11/16/22
- ANI Pharmaceuticals' Triimethoprim Tables USP approved by FDA
- 09/12/22
- ANI Pharmaceuticals names Krista Davis as Chief Human Resources Officer
- 02/27/23
- AbbVie receives CHMP opinion recommending approval for upadacitinib
- 02/23/23
- AbbVie, Capsida announce expanded genetic medicines for eye diseases pact
- 02/09/23
- AbbVie says 'high level of confidence' in achieving FY23 guidance
- 02/09/23
- AbbVie expects inflation to weigh on aesthetics business in 2023
- 03/01/23 RBC Capital
- Universal Health price target raised to $130 from $114 at RBC Capital
- 03/01/23 Stephens
- Universal Health price target lowered to $140 from $155 at Stephens
- 03/01/23 Wolfe Research
- Universal Health downgraded to Peer Perform at Wolfe after FY23 guidance
- 03/01/23 Wolfe Research
- Universal Health downgraded to Peer Perform from Outperform at Wolfe Research
- 03/01/23 UBS
- Procter & Gamble upgraded to Buy from Neutral at UBS
- 02/16/23 Citi
- Citi launches beverage, personal space with six buys, two sells
- 02/16/23 Citi
- Procter & Gamble initiated with a Buy at Citi
- 01/20/23 Stifel
- Procter & Gamble price target raised to $147 from $139 at Stifel
- 03/01/23 UBS
- UBS upgrades Philip Morris to Buy into heated tobacco launches
- 03/01/23 UBS
- Philip Morris upgraded to Buy from Neutral at UBS
- 02/02/23 Morgan Stanley
- Philip Morris price target raised to $118 from $109 at Morgan Stanley
- 01/25/23 Goldman Sachs
- Philip Morris upgraded to Buy from Neutral at Goldman Sachs
- 03/01/23 Benchmark
- MKS Instruments upgraded to Buy at Benchmark ahead of cyclical upswing in 2024
- 03/01/23 Wells Fargo
- MKS Instruments price target raised to $95 from $90 at Wells Fargo
- 03/01/23 Benchmark
- MKS Instruments upgraded to Buy from Hold at Benchmark
- 01/30/23 Deutsche Bank
- MKS Instruments price target raised to $110 from $90 at Deutsche Bank
- $151.32 /
+29.13 (+23.84%) - 03/01/23 RBC Capital
- Sarepta price target raised to $226 from $195 at RBC Capital
- 03/01/23 Oppenheimer
- Sarepta price target raised to $180 from $150 at Oppenheimer
- 03/01/23 Credit Suisse
- Sarepta price target raised to $144 from $137 at Credit Suisse
- 03/01/23 Needham
- Needham ups Sarepta target to $200, adds to Conviction list
- 03/01/23 Craig-Hallum
- Craig-Hallum downgrades Grocery Outlet to Hold, cuts price target to $29
- 03/01/23 Craig-Hallum
- Grocery Outlet downgraded to Hold from Buy at Craig-Hallum
- 12/19/22 Credit Suisse
- Grocery Outlet initiated with a Neutral at Credit Suisse
- 11/09/22 Deutsche Bank
- Grocery Outlet price target lowered to $41 from $43 at Deutsche Bank
- 03/01/23 Bernstein
- Spirit AeroSystems downgraded to Market Perform from Outperform at Bernstein
- 02/13/23 Barclays
- Spirit AeroSystems price target raised to $50 from $42 at Barclays
- 02/09/23 Bernstein
- Spirit AeroSystems price target raised to $46 from $41 at Bernstein
- 02/08/23 Susquehanna
- Spirit AeroSystems price target raised to $44 from $40 at Susquehanna
- 03/01/23 B. Riley
- iHeartMedia price target lowered to $16 from $22 at B. Riley
- 03/01/23 JPMorgan
- iHeartMedia downgraded to Underweight from Neutral at JPMorgan
- 02/28/23 Wells Fargo
- iHeartMedia price target lowered to $8 from $10 at Wells Fargo
- 01/17/23 B. Riley
- iHeartMedia price target lowered to $22 from $23 at B. Riley
- 03/01/23 DA Davidson
- Marqeta price target lowered to $5.00 from $7.25 at DA Davidson
- 03/01/23 Credit Suisse
- Marqeta price target lowered to $8 from $13.50 at Credit Suisse
- 03/01/23 JPMorgan
- Marqeta downgraded to Neutral from Overweight at JPMorgan
- 02/28/23 Morgan Stanley
- Marqeta price target lowered to $8 from $14 at Morgan Stanley
- 03/01/23 Guggenheim
- Johnson & Johnson initiated with a Neutral, $161 price target at Guggenheim
- 02/28/23 Guggenheim
- Johnson & Johnson initiated with a Neutral at Guggenheim
- 02/07/23 RBC Capital
- Arrowhead price target lowered to $77 from $83 at RBC Capital
- 02/06/23 Piper Sandler
- Arrowhead price target lowered to $52 from $55 at Piper Sandler
- 03/01/23 RBC Capital
- Rivian Automotive price target lowered to $28 from $50 at RBC Capital
- 03/01/23 DA Davidson
- Rivian Automotive price target lowered to $16 from $23 at DA Davidson
- 03/01/23 Canaccord
- Rivian Automotive price target lowered to $40 from $55 at Canaccord
- 03/01/23 Wedbush
- Rivian Automotive price target lowered to $25 from $37 at Wedbush
- 03/01/23 Guggenheim
- Guggenheim starts AbbVie with a Buy on diversified growth
- 02/28/23 Guggenheim
- AbbVie initiated with a Buy at Guggenheim
- 02/22/23 BMO Capital
- AbCellera price target lowered to $32 from $40 at BMO Capital
- 02/22/23 Wolfe Research
- AbbVie downgraded to Peer Perform on valuation at Wolfe Research
- 03/01/23 DA Davidson
- Palantir initiated with a Neutral at DA Davidson
- 02/28/23 DA Davidson
- Palantir initiated with a Neutral at DA Davidson
- 02/22/23 Deutsche Bank
- Palantir 2023 outlook 'certainly not without risk,' says Deutsche Bank
- 02/21/23 William Blair
- William Blair sees three of Palantir's four largest contracts as 'in play'
- 03/01/23 Guggenheim
- Guggenheim starts ANI Pharmaceuticals at Buy on cortrophin gel's potential
- 02/28/23 Guggenheim
- ANI Pharmaceuticals initiated with a Buy at Guggenheim
- 09/07/22 H.C. Wainwright
- ANI Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/16/22 Raymond James
- ANI Pharmaceuticals price target lowered to $47 from $65 at Raymond James
- 03/01/23 Redburn
- Spotify upgraded to Buy from Neutral at Redburn
- 02/06/23 Wells Fargo
- Spotify upgraded to Overweight from Equal Weight at Wells Fargo
- 02/06/23 Atlantic Equities
- Spotify upgraded to Overweight from Neutral at Atlantic Equities
- 02/01/23 Truist
- Spotify price target raised to $132 from $115 at Truist
- 02/27/23
- Universal Health sees FY23 adjusted EPS of $9.50-$10.50, consensus $10.79
- 02/27/23
- Universal Health reports Q4 adjusted EPS $3.02, consensus $2.96
- 02/27/23
- Notable companies reporting after market close
- 10/25/22
- Universal Health reports Q3 adjusted EPS $2.54, consensus $3.43
- $151.32 /
+29.13 (+23.84%) - 02/28/23
- Sarepta reports Q4 EPS ($1.24), consensus ($1.35)
- 01/09/23
- Sarepta expects to exceed FY22 guidance for net product revenues
- 11/02/22
- Sarepta reports Q EPS (80c), consensus (1.43)
- 02/07/23
- Spirit AeroSystems reports Q4 adjusted EPS ($1.46), consensus (21c)
- 02/06/23
- Notable companies reporting before tomorrow's open
- 11/03/22
- Spirit AeroSystems reports Q3 EPS (15c), consensus (40c)
- 01/31/23
- Spotify sees Q1 revenue EUR 3.1B, gross margin 24.9%
- 01/31/23
- Spotify reports Q4 EPS (EUR 1.40) vs. (EUR 0.20) last year
- 10/25/22
- Spotify reports Q3 Operating loss EUR (228M) vs. profit EUR 75M prior
- 02/28/23
- Rivian Automotive reports Q4 adjusted EPS ($1.73), consensus ($1.94)
- 02/02/23
- Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c
- 11/09/22
- Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82)
- 02/09/23
- Philip Morris sees FY23 adjusted EPS, ex-currency $6.40-$6.52, consensus $5.90
- 02/09/23
- Philip Morris sees FY23 currency-neutral adjusted EPS growth of 7%-9%
- 02/09/23
- Philip Morris reports Q4 adjusted EPS ex-RU/UA $1.23, consensus $1.24
- 02/08/23
- Notable companies reporting before tomorrow's open
- 02/13/23
- Palantir sees FY23 revenue $2.18B-$2.23B, consensus $2.29B
- 02/13/23
- Palantir sees Q1 revenue $503M-$507M, consensus $520M
- 02/13/23
- Palantir reports Q4 adjusted EPS 4c, consensus 3c
- 02/13/23
- Notable companies reporting after market close
- 01/19/23
- Procter & Gamble raises FY23 sales growth outlook
- 01/19/23
- Procter & Gamble reports Q2 core EPS $1.59, consensus $1.59
- 01/18/23
- Notable companies reporting before tomorrow's open
- 02/28/23
- Marqeta sees Q1 net revenue growth 26%-28%, consensus $214.08M
- 02/28/23
- Marqeta reports Q4 EPS (5c), consensus (9c)
- 02/28/23
- Notable companies reporting after market close
- 11/09/22
- Marqeta sees Q4 revenue up 29%-31%, consensus $191M
- 02/27/23
- MKS Instruments sees Q1 revenue ex-ransomware impact $1B, consensus $928.16M
- 02/27/23
- MKS Instruments reports Q4 EPS $2.00, consensus $1.34
- 02/27/23
- MKS Instruments reports Q4 adjusted EPS $2.00, consensus $1.34
- 11/02/22
- MKS Instruments sees Q4 EPS $1.34 +/- 27c, consensus $2.26
- 02/28/23
- Fate Therapeutics reports Q4 EPS (58c), consensus (86c)
- 01/30/23
- Johnson & Johnson to challenge federal appeals court ruling
- 01/24/23
- Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33
- 01/24/23
- Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60
- 02/28/23
- iHeartMedia sees Q1 revenue down mid-single digits
- 02/28/23
- iHeartMedia reports Q4 adjusted EBITDA $316M, up 7% from last year
- 11/03/22
- iHeartMedia sees Q4 revenue growth 2%-6%, consensus $1.14B
- 11/03/22
- iHeartMedia reports Q3 revenue $989M, consensus $975.44M
- 02/28/23
- Grocery Outlet sees FY23 EPS 94c-99c, consensus $1.14
- 02/28/23
- Grocery Outlet reports Q4 EPS 25c, consensus 23c
- 11/08/22
- Grocery Outlet narrows FY22 adjusted EPS guidance to $1.00 from 97c-$1.00,
- 11/08/22
- Grocery Outlet reports Q3 adjusted EPS 27c, consensus 26c
- 11/09/22
- ANI Pharmaceuticals backs FY22 adjusted EPS view $1.34-$1.62, consensus $1.37
- 11/09/22
- ANI Pharmaceuticals reports Q3 adjusted EPS 64c, consensus 55c
- 02/09/23
- AbbVie sees Q1 adjusted EPS $2.39-$2.49, consensus $3.08
- 02/09/23
- AbbVie sees FY23 revenue about $52B, consensus $54.21B
- 02/09/23
- AbbVie sees FY23 adjusted EPS $10.70-$11.10, consensus $11.65
- 02/09/23
- AbbVie reports Q4 adjusted EPS $3.60, consensus $3.56
- 02/28/23
- EU narrows Apple probe to app restrictions, FT reports
- 02/10/23
- ValueAct takes stake in Spotify, Bloomberg reports
- 12/13/22
- Spotify steps back from live audio programming, Bloomberg says
- 10/26/22
- Spotify to raise prices in U.S. in 2023, WSJ reports
- 02/03/23
- Rivian Automotive to expand lineup with development of e-bike, Bloomberg says
- 02/03/23
- Rivian CEO says working on electric bikes, Bloomberg reports
- 02/01/23
- Rivian Automotive to reduce workforce by 6%, Reuters reports
- 02/01/23
- Rivian Automotive cutting workforce by 6%, Reuters reports
- 01/25/23
- Juul in deal discussions with Philip Morris, Altria, Japan Tobacco, WSJ says
- 01/21/23
- Wells Fargo, Disney among stocks watched by value investors, Barron's says
- 01/07/23
- Philip Morris' stock about to get 'smoking hot,' Barron's says
- 12/12/22
- Supreme Court declines to halt California flavored tobacco ban, Bloomberg says
- 02/27/23
- Palantir tells Bloomberg 2% of workforce to be cut
- 10/17/22
- Procter & Gamble bets inflation won't push shoppers to swap brands, WSJ reports
- 10/10/22
- Environmentalists to challenge P&G CEO as chairman, Reuters says
- 02/01/23
- Novavax refuses to refund $700M for COVID shots never delivered, NY Times says
- 01/30/23
- Appeals court dismisses Chapter 11 case of J&J unit, WSJ reports
- 01/13/23
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- 01/09/23
- J&J may look for deals that boost eye care, surgical robots units, Reuters says
- 02/06/23
- AbbVie looking for next hit drug after competitors target Humira, WSJ reports
- 01/31/23
- AbbVie's Humira drug faces competition in the U.S., FT reports
- 12/03/22
- Buy AbbVie, stock still worth owning even as Humira fades, Barron's says
- 11/16/22
- Optum Rx puts biosimilars on formulary against AbbVie's Humira, Bloomberg says
- 02/27/23
- Fly Intel: After-Hours Movers
- 01/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/25/22
- Fly Intel: After-Hours Movers
- $151.32 /
+29.13 (+23.84%) - 02/28/23
- Fly Intel: After-Hours Movers
- 01/09/23
- What You Missed On Wall Street On Monday
- 12/16/22
- What You Missed On Wall Street On Friday
- 12/16/22
- What You Missed On Wall Street This Morning
- 02/07/23
- Fly Intel: Pre-market Movers
- 11/11/22
- What You Missed On Wall Street On Friday
- 11/11/22
- What You Missed On Wall Street This Morning
- 11/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/11/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 02/10/23
- What You Missed On Wall Street This Morning
- 02/06/23
- What You Missed On Wall Street On Monday
- 02/27/23
- What You Missed This Week in EVs and Clean Energy
- 02/22/23
- Here's what Wall Street experts are saying about these EV names ahead of results
- 02/09/23
- Fly Intel: Pre-market Movers
- 01/25/23
- What You Missed On Wall Street On Wednesday
- 01/25/23
- What You Missed On Wall Street This Morning
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/14/23
- What You Missed On Wall Street On Tuesday
- 02/14/23
- What You Missed On Wall Street This Morning
- 02/14/23
- Fly Intel: Pre-market Movers
- 02/13/23
- Fly Intel: After-Hours Movers
- 01/19/23
- What You Missed On Wall Street On Thursday
- 01/19/23
- What You Missed On Wall Street This Morning
- 01/19/23
- Fly Intel: Pre-market Movers
- 11/26/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 03/01/23
- Fly Intel: Pre-market Movers
- 11/11/22
- Sell these stocks now, proven algorithm says
- 11/10/22
- What You Missed On Wall Street On Thursday
- 12/23/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/20/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/24/23
- What You Missed On Wall Street This Morning
- 11/03/22
- Fly Intel: After-Hours Movers
- 10/31/22
- Fly Insider: Streamline Health, Deere among week's notable insider trades
- 02/22/23
- What You Missed On Wall Street On Wednesday
- 02/22/23
- What You Missed On Wall Street This Morning
- 02/22/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/10/23
- What You Missed On Wall Street On Friday
- 10/26/22
- Early notable gainers among liquid option names on October 26th
- 10/24/22
- Early notable gainers among liquid option names on October 24th
- 12/29/22
- Largest borrow rate increases among liquid names
- 02/10/23
- Spotify call volume above normal and directionally bullish
- 01/31/23
- Unusually active option classes on open January 31st
- 01/23/23
- Unusually active option classes on open January 23rd
- 01/19/23
- Spotify call volume above normal and directionally bullish
- 02/28/23
- Rivian options imply 11.8% move in share price post-earnings
- 02/02/23
- Rivian call volume above normal and directionally bullish
- 01/31/23
- Rivian call volume above normal and directionally bullish
- 01/27/23
- Rivian call volume above normal and directionally bullish
- 02/24/23
- Philip Morris call volume above normal and directionally bullish
- 01/19/23
- Early notable gainers among liquid option names on January 19th
- 10/31/22
- Philip Morris put volume heavy and directionally bearish
- 09/23/22
- Philip Morris put volume heavy and directionally bearish
- 02/15/23
- Unusually active option classes on open February 15th
- 02/13/23
- Palantir Technologies call volume above normal and directionally bullish
- 02/08/23
- Palantir Technologies call volume above normal and directionally bullish
- 02/06/23
- Palantir Technologies call volume above normal and directionally bullish
- 01/25/23
- Procter & Gamble call volume above normal and directionally bullish
- 01/19/23
- Unusually active option classes on open January 19th
- 01/11/23
- Largest borrow rate increases among liquid names
- 11/21/22
- Unusually active option classes on open November 21st
- 11/09/22
- Marqeta options imply 11.6% move in share price post-earnings
- 01/31/23
- Johnson & Johnson put buyer realizes 135% same-day gains
- 01/30/23
- Johnson & Johnson put volume heavy and directionally bearish
- 01/24/23
- Unusually active option classes on open January 24th
- 01/20/23
- Johnson & Johnson put buyer realizes 33% same-day gains
- 02/09/23
- Unusually active option classes on open February 9th
- 01/18/23
- Unusually active option classes on open January 18th
- 10/28/22
- Unusually active option classes on open October 28th
|